Doctoral (PhD) student position in Evolutionary selection of DNA structures for detection and inhibition of pathogens Department of Microbiology, Tumor and Cell Biology 2025-12-03 PhD position in fat ...

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...